Search
ProKidney Corp
PROKAdd to Watchlist
1.660USD
-0.050-2.92%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
235.40MMarket Cap
LossP/E TTM
More Details of ProKidney Corp Company
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
ProKidney Corp Info
Ticker SymbolPROK
Company nameProkidney Corp
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Number of employees204
Security typeOrdinary Share
Fiscal year-endJun 30
Address2000 Frontis Plaza Blvd
CityWINSTON-SALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27103
Phone13369997028
Websitehttps://prokidney.com/
Ticker SymbolPROK
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Company Executives of ProKidney Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Control Empresarial de Capitales, S.A. de C.V.
52.01%
Tolerantia LLC
15.93%
Suvretta Capital Management, LLC
8.69%
Morgan Stanley Investment Management Inc. (US)
6.00%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Other
14.96%
Shareholders
Shareholders
Proportion
Control Empresarial de Capitales, S.A. de C.V.
52.01%
Tolerantia LLC
15.93%
Suvretta Capital Management, LLC
8.69%
Morgan Stanley Investment Management Inc. (US)
6.00%
BlackRock Mexico Operadora SA de CV SOFI
2.42%
Other
14.96%
Shareholder Types
Shareholders
Proportion
Corporation
67.94%
Hedge Fund
12.19%
Investment Advisor
11.75%
Investment Advisor/Hedge Fund
8.07%
Research Firm
1.58%
Individual Investor
0.91%
Endowment Fund
0.70%
Pension Fund
0.09%
Bank and Trust
0.04%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
181
50.49M
35.56%
+4.72M
2025Q4
178
41.09M
29.03%
-2.44M
2025Q3
180
38.60M
28.59%
-15.99M
2025Q2
187
92.52M
71.43%
-12.19M
2025Q1
188
90.99M
70.46%
-13.35M
2024Q4
184
92.39M
74.12%
+21.48M
2024Q3
176
90.75M
73.53%
+26.28M
2024Q2
216
81.85M
70.67%
+19.77M
2024Q1
231
37.73M
58.52%
-31.32M
2023Q4
239
39.92M
63.74%
-31.95M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Control Empresarial de Capitales, S.A. de C.V.
10.72M
7.56%
+2.28M
+27.04%
Apr 22, 2025
Tolerantia LLC
22.62M
15.93%
--
--
Jun 03, 2025
Suvretta Capital Management, LLC
12.34M
8.69%
--
--
Dec 31, 2025
Morgan Stanley Investment Management Inc. (US)
8.52M
6%
+2.11M
+32.90%
Dec 31, 2025
BlackRock Mexico Operadora SA de CV SOFI
3.43M
2.42%
--
--
Feb 28, 2026
Operadora de Fondos GBM S.A.B. de C.V.
2.45M
1.73%
--
--
Feb 28, 2026
Bleichroeder LP
2.00M
1.41%
--
--
Dec 31, 2025
Artia Global Partners LP
1.84M
1.3%
+1.84M
--
Dec 31, 2025
Millennium Management LLC
1.83M
1.29%
-121.84K
-6.23%
Dec 31, 2025
Hennion & Walsh Asset Management, Inc.
1.50M
1.06%
+583.98K
+63.48%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Schwab U.S. Small-Cap ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Schwab U.S. Broad Market ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
View more
Schwab U.S. Small-Cap ETF
Proportion0.01%
ALPS Medical Breakthroughs ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
